Evidence map›Paper›PMID 37823722›Full record

ArticleEuropean journal of neurology2024

Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.

Alberto Calvi, Zoe Mendelsohn, Weaam Hamed, Declan Chard, Carmen Tur, Jon Stutters, David MacManus, Baris Kanber, Claudia A M Gandini Wheeler-Kingshott, Frederik Barkhof and 1 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00731692 (A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00731692 phase3terminatednot on this map

A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis

TypeinterventionalSponsorNovartis PharmaceuticalsRan2008 to 2015Enrolled970ConditionsPrimary Progressive Multiple SclerosisArmsFTY720, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024
    Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

Alberto CalviNMR Research Unit, Institute of Neurology, University College London, London, UK.ORCID 0000-0002-1953-2803
Zoe MendelsohnNMR Research Unit, Institute of Neurology, University College London, London, UK.
Weaam HamedNMR Research Unit, Institute of Neurology, University College London, London, UK.
Declan ChardNMR Research Unit, Institute of Neurology, University College London, London, UK.
Carmen TurNMR Research Unit, Institute of Neurology, University College London, London, UK.
Jon StuttersNMR Research Unit, Institute of Neurology, University College London, London, UK.ORCID 0000-0002-9151-0844
David MacManusNMR Research Unit, Institute of Neurology, University College London, London, UK.
Baris KanberNational Institute for Health Research, Biomedical Research Centre, University College London Hospitals, London, UK.
Claudia A M Gandini Wheeler-KingshottNMR Research Unit, Institute of Neurology, University College London, London, UK.
Frederik BarkhofNMR Research Unit, Institute of Neurology, University College London, London, UK.
Ferran PradosNMR Research Unit, Institute of Neurology, University College London, London, UK.
University College London · GBNational Institute for Health Research · GBAmsterdam University Medical Centers · NLFundació Clínic per a la Recerca Biomèdica · ESMansoura University Hospital · EGUniversitat Oberta de Catalunya · ESUniversity of Pavia · ITVall d'Hebron Hospital Universitari · ES

Funding

Multiple Sclerosis Society
6 · The paper itself

Abstract

background and purposeNewly appearing lesions in multiple sclerosis (MS) may evolve into chronically active, slowly expanding lesions (SELs), leading to sustained disability progression. The aim of this study was to evaluate the incidence of newly appearing lesions developing into SELs, and their correlation to clinical evolution and treatment.

methodsA retrospective analysis of a fingolimod trial in primary progressive MS (PPMS; INFORMS, NCT00731692) was undertaken. Data were available from 324 patients with magnetic resonance imaging scans up to 3 years after screening. New lesions at year 1 were identified with convolutional neural networks, and SELs obtained through a deformation-based method. Clinical disability was assessed annually by Expanded Disability Status Scale (EDSS), Nine-Hole Peg Test, Timed 25-Foot Walk, and Paced Auditory Serial Addition Test. Linear, logistic, and mixed-effect models were used to assess the relationship between the Jacobian expansion in new lesions and SELs, disability scores, and treatment status.

resultsOne hundred seventy patients had ≥1 new lesions at year 1 and had a higher lesion count at screening compared to patients with no new lesions (median = 27 vs. 22, p = 0.007). Among the new lesions (median = 2 per patient), 37% evolved into definite or possible SELs. Higher SEL volume and count were associated with EDSS worsening and confirmed disability progression. Treated patients had lower volume and count of definite SELs (β = -0.04, 95% confidence interval [CI] = -0.07 to -0.01, p = 0.015; β = -0.36, 95% CI = -0.67 to -0.06, p = 0.019, respectively).

conclusionsIncident chronic active lesions are common in PPMS, and fingolimod treatment can reduce their number.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveFingolimod HydrochlorideHumansIncidenceMagnetic Resonance ImagingRetrospective StudiesFingolimod Hydrochloridechronic active lesionsfingolimodprimary progressive multiple sclerosisslowly expanding lesions (SELs)volumetric MRI

Identifiers

PMID37823722
PMCPMC11236028
OpenAlexW4387563486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.